Aimed Bio Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
11:00
Jan 03
Jan 03
JPM healthcare may lift license-out biotechs
After CES, the JP Morgan Healthcare conference may relay momentum into Korean biotechs with prior license-out experience, including Aimed Bio, Alzinomics, OliX, Alteogen, and ABL; expectations are rising.
MED
About Aimed Bio Investor Commentary
Across the available history and selected sources, Buzzberg tracks Aimed Bio across 1 sources: 0 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 0% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: Lee Ju-hyeon.